Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
Webinar Insights | The Rise of Competitive Rare Diseases: European Payer Perspectives
CRA recently hosted a webinar with leading European payer experts to discuss the increasingly competitive rare disease (RD) landscape